Vertex Pharmaceuticals (VRTX) EVP logs 4,500-share 10b5-1 sale

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Ourania Tatsis, EVP and Chief Regulatory & Quality Officer, reported selling 4,500 shares of Vertex common stock on 01/07/2026 at a price of $474.99 per share. After this transaction, she beneficially owned 42,293 shares, all held directly.

The filing notes that the sale was made pursuant to Dr. Tatsis’ company-approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Such plans are pre-arranged programs that allow insiders to sell stock according to preset terms, helping them diversify holdings while addressing concerns about trading on material nonpublic information.

Insider Trade Summary

Net Seller: 4,500 shares ($2,137,455)

Net Sell 1 txn

Insider Tatsis Ourania

Role EVP, Chief Reg. & Quality Off.

Sold 4,500 shs ($2.14M)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,500	$474.99	$2.14M

Holdings After Transaction: Common Stock — 42,293 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		S(1)		4,500	D	$474.99	42,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VRTX disclose for Ourania Tatsis?

The filing reports that EVP, Chief Regulatory & Quality Officer Ourania Tatsis sold 4,500 shares of Vertex common stock on 01/07/2026.

At what price were the Vertex (VRTX) shares sold by the EVP?

The 4,500 shares of Vertex common stock were sold at a price of $474.99 per share.

How many VRTX shares does the executive own after this transaction?

Following the reported sale, Ourania Tatsis beneficially owned 42,293 Vertex common shares, held in direct ownership.

Was the Vertex EVP’s stock sale made under a Rule 10b5-1 trading plan?

Yes. The transaction was made under a company-approved Rule 10b5-1 trading plan that Dr. Tatsis entered into on 08/21/2025.

What role does the reporting person hold at Vertex Pharmaceuticals (VRTX)?

The reporting person, Tatsis Ourania, serves as EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals.

Is this Form 4 for direct or indirect ownership of VRTX shares?

The Form 4 shows the shares sold and the remaining 42,293 shares as directly owned by the reporting person.